AstraZeneca Pharmaceuticals LP
NEWS
Companies share robust oncology data at annual ASCO meeting.
Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
Full data will be shared at a later conference, but the study marked the first time a BTK inhibitor showed benefit as a monotherapy in CLL.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
JOBS
IN THE PRESS